Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

December 16, 2019

Genentech announces results of IMspire150 study in BRAF V600 mutation-positive advanced melanoma

Genentech, a member of the Roche Group, announced the Phase III IMspire150 study, in people with previously untreated BRAF V600 mutation-positive advanced melanoma, met its primary endpoint of progression-free survival (PFS).

Genentech announces results of IMspire150 study in BRAF V600 mutation-positive advanced melanoma